NFKB1 and atopic eczema: demonstrated that Tat and AT1002 peptides could accelerate transdermal siRNA delivery both widely and effectively (13); topical skin application of anti-NF-κB (RelA) siRNA with STR-CH2R4H2C and AT1002 improved atopic dermatitis-like symptoms in model mice (17).